Regenerative is the word London clinics currently use for treatments that aim to improve the quality of tissue rather than change its shape. The category has grown quickly, the marketing has grown faster, and patients are being asked to choose between products whose evidence bases differ by an order of magnitude. This guide sorts the main categories by how settled each one actually is.
What regenerative actually means here
Conventional injectable treatment either relaxes muscle or adds volume. Regenerative treatment aims instead to stimulate the skin's own repair processes, so that the improvement comes from the tissue rather than from the product occupying space. That is a genuinely different proposition, and it explains three things patients find frustrating: results are gradual, they are usually delivered as a course, and they are harder to photograph convincingly.
It also explains why the category attracts overstatement. A treatment whose effect is real but subtle is commercially harder to sell than one whose effect is immediate, and the temptation to reach for the language of stem cells and cellular renewal is strong. The useful discipline for a patient is to ask which regulatory category the product sits in and what published evidence supports the specific use being proposed.
The established end
Hyaluronic acid skin boosters
Injected hyaluronic acid formulated to hydrate and improve skin quality rather than to add structural volume. Delivered in a series of small injections across an area, typically three sessions spaced two to four weeks apart, with maintenance every six to nine months. Widely used across London, well tolerated, with the same product category and regulatory status as dermal filler. Indicative price £250 to £500 per session.
Platelet-rich plasma
Your own blood is drawn, spun in a centrifuge to concentrate the platelet fraction, and reinjected into skin or scalp. It has been used in aesthetics for well over a decade and in other areas of medicine for longer, which makes it the most familiar of the regenerative options. Preparation methods vary considerably between clinics, and that variation is one reason published results differ. Because it involves handling blood, premises standards, training and consent matter more than for a standard injectable. Indicative price £350 to £700 per session, usually three sessions.
The rapidly growing middle
Polynucleotides
Purified DNA fragments, most commonly derived from salmon or trout, injected into the skin with the aim of supporting fibroblast activity and tissue repair. They have moved from niche to near-standard in London clinics over the last few years, particularly for the under-eye area, for skin quality on the face and neck, and increasingly for the scalp. Treatment is typically a course of three, spaced two to four weeks apart, with results developing over the following months. Indicative price £280 to £550 per session.
The category is more established in some European markets than in the United Kingdom, and the quality of a given product depends on its purification and its molecular profile, which are not visible to the patient. Ask which product is being used, and ask what its regulatory status is.
The emerging and unsettled end
Exosome-based protocols
Exosomes are small extracellular vesicles that carry signalling molecules between cells. In laboratory and preclinical research they are a legitimate and active field. In aesthetic clinics they appear in a very different form, most often as a topical preparation applied to skin or scalp immediately after microneedling or laser, so that the disrupted barrier allows greater penetration.
Two things patients should understand. First, the regulatory position is not the same as for a licensed medicine. Products of this kind sit in a complex and evolving space, and a product being available for purchase is not the same as a product being licensed for a therapeutic claim. Second, the published clinical evidence in aesthetic use is early. There is reasonable mechanistic rationale and there are promising early reports. There is not yet the weight of trial evidence that supports, for example, botulinum toxin.
That does not make the category worthless. It makes it a category where the practitioner should be telling you plainly that it is emerging, what is known, what is not, and why they think it is worth your money anyway. A practitioner who presents it as settled science is either not reading the literature or is choosing not to describe it accurately.
The test for any regenerative treatment is simple: can the practitioner tell you what the product is, what its regulatory status is, and what evidence supports this specific use?
How the categories compare
| Category | Maturity in UK practice | Typical course | Indicative price |
|---|---|---|---|
| Hyaluronic acid skin boosters | Established | 3 sessions | £250 to £500 each |
| Platelet-rich plasma | Established, variable preparation | 3 sessions | £350 to £700 each |
| Polynucleotides | Rapidly mainstreaming | 3 sessions | £280 to £550 each |
| Exosome-based protocols | Emerging, evidence early | 3 to 4 sessions | £400 to £900 each |
The questions worth asking
- What is the product called, who makes it, and what is its regulatory status in the United Kingdom?
- What published evidence supports this specific use in this specific area?
- What result should I expect, on what timescale, and how will we judge whether it worked?
- What happens if it does not work, and what is the plan then?
- If blood is being handled, what are your premises standards and your training for that?
The fourth question is the one that most reliably distinguishes a clinical plan from a sales process. Regenerative treatments do not work for everyone, and a practitioner who has thought about the non-responders is a practitioner who has thought about you.
Where these treatments cluster in London
Adoption is fastest in Shoreditch, where new protocols arrive first and where the gap between marketing and evidence is widest. Chiswick and Wimbledon Village practitioners tend to adopt later and more conservatively, which suits patients who want to be second rather than first. Central London sits between the two, with the added advantage that a dermatological second opinion is available in the same building if a result is unexpected. The category itself is reasonable. The variation in how it is sold is what should govern where you have it done.